Microviable Therapeutics was in the group of technology-based companies that the CSIC presented at Transfiere 2020, the European Forum for Science, Technology and Innovation, which was held in Malaga on 12 and 13 February.

During the event, Rafael Martinez Permuy, CEO at Microviable, commented that the microbiota is already related to about 120 diseases and points out the need for a gut microbiota storage system for future therapeutic applications in the line of the “library” that the company is creating.

Rafael highlighted also the sale of more than 600 Gutalive kits for the collection of stool samples in anaerobiosis and the EC Seal of Excellence in H2020 received by the company.

View more at Infosalus